Get the Stockscreener App
256.90
1.18%
3.60
After Hours:
255.46
-1.44
-0.56%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $256.90, with a volume of 3.02M.
It is up +1.18% in the last 24 hours and up +9.17% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$253.30
Open:
$253.98
24h Volume:
3.02M
Relative Volume:
0.44
Market Cap:
$453.89B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
126.71
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+0.75%
1M Performance:
+9.17%
6M Performance:
+16.89%
1Y Performance:
+34.50%
1-Day Range:
$253.10
$258.38
1-Week Range:
$252.25
$260.96
52-Week Range:
$187.62
$261.63
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
256.90 | 447.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,185.55 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.40 | 615.36B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
130.46 | 314.83B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.18 | 290.96B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie: Bright Future, But Already Priced In (NYSE:ABBV) - Seeking Alpha
I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation - The Motley Fool
Donald TrumpABBVIE INC COM UNSOLICITED Trump Trade on Mar. 25, 2026 - Quiver Quantitative
AbbVie stock holds near record levels after second-quarter results - Ad-hoc-news.de
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Total equity of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs - Bloomberg Law News
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2? - TradingView
Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating - marketscreener.com
Canaccord raises Abbvie stock price target to $282 on growth outlook - Investing.com
ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana - GuruFocus
ETFs Investing in AbbVie, Inc. Stocks - TradingView
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin - Yahoo Finance
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
EBIT per share of AbbVie, Inc. – BCS:ABBVCL1 - TradingView
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Enterprise value of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Stock Zigs When The Market Zags - Trefis
AbbVie stock advances on a strong 2025 base - Ad-hoc-news.de
J&J, Eli Lilly, or AbbVie? How to Play Big Pharma in a Diverging Market - finance.biggo.com
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal - Endpoints News
AbbVie’s Allergan gets European nod for its Botox-lite treatment - Crain's Chicago Business
A 54-Year Dividend Streak Meets a $10.9 Billion Acquisition: Here’s Why AbbVie’s Payouts Are Safe - NAI500
AbbVie stock holds firm as Humira biosimilar impact is offset by Skyrizi and Rinvoq growth - ad-hoc-news.de
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? - The Motley Fool
AbbVie stock trades steady as Skyrizi and Rinvoq drive double digit revenue growth - ad-hoc-news.de
AbbVie stock trades steady as investors focus on Skyrizi and Rinvoq growth after mixed quarter - ad-hoc-news.de
AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe - Yahoo Finance UK
AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE) - Seeking Alpha
AbbVie stock holds gains as investors weigh Skyrizi and Rinvoq growth - ad-hoc-news.de
Is AbbVie Inc (ABBV) Overvalued After 4.2% Rally? GF Value Says - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress - ad-hoc-news.de
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - Yahoo Finance
Is AbbVie (NYSE:ABBV) Fully Valued After Tepkinly? - Kalkine Media
Why AbbVie (ABBV) Stock Is Up Today - Quiver Quantitative
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send? - TradingKey
Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow? - simplywall.st
AHA urges court to reject AbbVie bid to change 340B program rules - EIN News
AbbVie stock holds steady as its diversified portfolio underpins long-term growth - ad-hoc-news.de
ABBV Maintained by Citigroup -- Price Target Raised to $260 - GuruFocus
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? - TradingView
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap - Yahoo Finance
Nxera Pharma Webinar for Financial Results Presentation - GlobeNewswire Inc.
Red day on Tuesday for AbbVie stock after losing 1.31% - StockInvest.us
AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run - Yahoo Finance
AbbVie Tokenized Stock price today, ABBVX to USD chart, marketcap and volume - CryptoSlate
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (ABBV) Faces Seventh Consecutive Loss Amid Mixed Sentimen - GuruFocus
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.18%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):